Autres langues Polaris Group

Actions

6550

KYG7171A1085

Recherche biotechnologique et médicale

Cours en clôture Taiwan S.E. 31/08/2026			Varia. 5j.	Varia. 1 janv.
10,70 ^TWD	-4,46%		-12,65%	-65,59%

27/08	Polaris Group publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
18/08	Polaris va réduire son capital de 4,3 milliards de dollars taïwanais et prévoit de dissoudre deux filiales européennes	MT

Autres langues

27/08	Polaris Group Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
18/08	Polaris to Reduce Capital by NT$4.3 Billion; Plans to Dissolve Two European Units
14/05	Polaris Group Reports Earnings Results for the First Quarter Ended March 31, 2026
13/03	Polaris Group Reports Earnings Results for the Full Year Ended December 31, 2025
26/12	Polaris Group Announces Management Changes, Effective December 26, 2025
26/12	Polaris Group Announces Chief Executive Officer Changes, Effective December 26, 2025
26/12	Polaris Group announced that it will receive TWD 4.5 billion in funding
17/12	Polaris Group's CEO Resigns
16/12	Polaris Group Announces Resignation of Steve J.P. Hsu as Chief Executive Officer, Effective December 24, 2025
16/12	Polaris Group Names New Chairman; Shares Rally 10%
15/12	Polaris Group Announces Management Changes, Effective December 24, 2025
12/11	Polaris Group Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025
07/11	Polaris Group announced that it expects to receive TWD 3.2 billion in funding from Digital Capital Inc., Digital Mobile Venture Ltd.
01/09/25	Polaris Group Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025
19/08/25	Polaris Cancer Drug Candidate Enters FDA Substantive Review
21/07/25	Polaris Unit Grants Drug Distribution Rights to Bioprofarma Bago
11/06/25	Polaris Group Completes Submission of US FDA Application for Rare Lung Cancer Drug
10/06/25	Polaris Group Completes Rolling Submission of Biologic License Application for ADI-PEG 20 with FDA to Treat Malignant Pleural Mesothelioma
14/05/25	Polaris Group Reports Earnings Results for the First Quarter Ended March 31, 2025
25/04/25	Polaris Group Announces Changes in the Board of Directors on Behalf of Key Subsidiary Designerx Pharmaceuticals, Inc
25/04/25	Polaris Group Announces Changes in the Board of Directors on Behalf of Key Subsidiary DRx Pharmaceuticals, Inc
25/04/25	Polaris Group Announces Changes in Designated and Non-Designated Representatives, Effective April 25, 2025
15/04/25	Polaris Unit Signs Two Sales Deals for Malignant Pleural Mesothelioma Drug
09/04/25	Polaris' Taps CEO as Chairman
08/04/25	Polaris Group Announces Chairman Changes